SGLT2 Inhibitors and Ketone Metabolism in Heart Failure

Huitzilihuitl Saucedo-Orozco; Suzanne N Voorrips; Salva R Yurista; Rudolf A de Boer; B Daan Westenbrink

doi:10.12997/jla.2022.11.1.1

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure

J Lipid Atheroscler. 2022 Jan;11(1):1-19. doi: 10.12997/jla.2022.11.1.1. Epub 2022 Jan 13.

Authors

Huitzilihuitl Saucedo-Orozco¹, Suzanne N Voorrips¹, Salva R Yurista², Rudolf A de Boer¹, B Daan Westenbrink¹

Affiliations

¹ Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
² Cardiology Division, Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Abstract

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as powerful drugs that can be used to treat heart failure (HF) patients, both with preserved and reduced ejection fraction and in the presence or absence of type 2 diabetes. While the mechanisms underlying the salutary effects of SGLT2 inhibitors have not been fully elucidated, there is clear evidence for a beneficial metabolic effect of these drugs. In this review, we discuss the effects of SGLT2 inhibitors on cardiac energy provision secondary to ketone bodies, pathological ventricular remodeling, and inflammation in patients with HF. While the specific contribution of ketone bodies to the pleiotropic cardiovascular benefits of SGLT2 inhibitors requires further clarification, ketone bodies themselves may also be used as a therapy for HF.

Keywords: Heart failure; Inflammation; Ketone bodies; Sodium-glucose transporter 2 inhibitors; Ventricular remodeling.